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ABSTRACT	  Colorectal	  cancer	  is	  the	  second	  most	  common	  cancer	  that	  affects	  both	  women	  and	  men	  in	  the	   United	   States,	   with	   a	   50%	   five	   year	   survival	   if	   the	   disease	   is	   diagnosed	   with	   local	  metastases	  (Zeve	  and	  Chen,	  2009).	  More	  than	  80%	  of	  colorectal	  cancers	  are	  characterized	  by	  mutation	  of	  the	  APC	  tumor	  suppressor	  gene,	  named	  after	  the	  inherited	  disorder	  familial	  adenomatous	  polyposis	  coli	  in	  which	  germline	  APC	  mutation	  inevitable	  leads	  to	  colorectal	  cancer	   (Groden	   et	   al.,	   1991).	   APC	   functions	   as	   a	   major	   regulator	   of	   the	   WNT	   signaling	  pathway	   by	   controlling	    -­‐catenin	   levels	   in	   the	   nucleus	   and	   subsequent	   transcription	  patterns	   that	   promote	   differentiation	   (Logan	   and	   Nusse,	   2004).	   This	   work	   will	   test	   the	  hypothesis	   that	  APC	  has	  additional	   tumor	  suppressor	   functions	   independent	  of	  ß-­‐catenin	  regulation.	  Our	  published	  in	  vitro	  studies	  have	  supported	  this	  hypothesis	  by	  demonstrating	  APC	   functions	   in	   the	   inhibition	   of	   DNA	   replication	   in	   S-­‐phase	   and	   the	   promotion	   of	  apoptosis	   (Steigerwald	   et	   al.,	   2005;	  Qian	   et	   al.,	   2007,	   2008,	   2010).	   Additionally,	   APC	  has	  been	   reported	   to	  bind	   to	  an	  enhancer	   site	  upstream	  of	   the	  c-­‐MYC	  proto-­‐oncogene	  and	   to	  directly	  downregulate	  c-­‐MYC’s	  transcriptional	  activity	  (Sierra	  et	  al.,	  2006).	  Consistent	  with	  these	  reports,	  our	  preliminary	  RNA	  deep	  sequencing	  (RNA-­‐seq)	  data	  show	  that	  a	  colorectal	  cancer	   cell	   line	   with	   activated	  Wnt	   signaling	   exhibits	   different	   gene	   expression	   profiles	  when	   APC	   is	   knocked	   down	   compared	   to	  when	   APC	   is	   expressed	   normally.	   A	   particular	  interest	  of	  this	  resultant	  gene	  profile	  was	  a	  1.64	  fold	  increase	  in	  expression	  of	  the	  CDC25A	  oncogene	   when	   APC	   was	   knocked	   down	   (Figure	   1).	   CDC25A	   is	   a	   phosphatase	   that	  promotes	   the	   cell	   cycle	   by	   removing	   inactivating	   phosphorylations	   from	   the	   cyclin-­‐-­‐‐dependent	  kinases	  Cdk2	  and	  Cdk4	  (Ray	  et	  al.,	  2007).	  We	  hypothesize	  that	  the	  loss	  of	  APC	  results	   in	   the	   direct	   upregulation	   of	   CDC25A	   transcript.	   The	   loss	   of	   CDC25A	   regulation	  
drives	   the	  cell	   cycle	   to	  a	  much	  more	  rapid	  rate	  similar	   to	   that	  seen	   in	  colorectal	  cancers.	  The	  direct	  binding	  of	  APC	  to	  specific	  chromatin	  could	  directly	  influence	  tumorigenesis	  and	  would	  suggest	  the	  need	  to	  consider	  new	  therapeutic	  approaches	  to	  the	  treatment	  of	  human	  colorectal	  tumors	  without	  APC.	  
	  
INTRODUCTION	  Colorectal	  cancer	  is	  the	  second	  leading	  cause	  of	  cancer	  related	  deaths	  in	  the	  Western	  world	  and	  is	  currently	  the	  third	  most	  common	  form	  of	  cancer	  (Zeve	  and	  Chen,	  2009).	  In	  order	  to	  develop	   better	   diagnostic	   tests	   and	   patient	   treatments,	   it	   is	   vital	   to	   improve	   our	  understanding	   of	   the	   pathological	   progression	   of	   this	   disease.	   One	   promising	   area	   of	  research	  is	  determining	  the	  consequences	  of	  mutations	  in	  adenomatous	  polyposis	  coli	  (APC)	  gene,	  which	   are	   found	   in	   approximately	   80%	  of	   colorectal	   cancers	   (Kinzler	   et	   al.,	   2000).	  Loss	   of	   APC	   leads	   to	   the	   constitutive	   activation	   of	   the	   Wnt	   signaling	   pathway,	   which	  controls	   the	   transcription	   of	  many	   essential	   genes	   in	   development,	   cellular	   proliferation,	  and	  differentiation.	   	  Loss	  of	  this	  transcriptional	  regulation	  by	  APC	   leads	  to	  sporadic	  polyp	  formation	   in	   the	   colorectal	   epithelium	   (Groden	   et	   al.,	   1991).	   If	   not	   removed,	   this	   pre-­‐cancerous	  polyp	  will	  progress	  into	  a	  malignant	  tumor.	  Therefore,	   it	   is	  vital	  to	  identify	  the	  functions	   of	   APC	   that	   are	   most	   important	   in	   polyp	   formation	   and	   in	   the	   subsequent	  development	  of	  cancer.	  	  	  APC	  has	  long	  been	  known	  to	  regulate	  the	  transcription	  of	  cancer	  related	  genes	  indirectly,	  by	   targeting	   the	  Wnt	   pathway’s	   key	   transcriptional	   regulator	  β-­‐catenin	   for	   degradation	  (Logan	  and	  Nusse,	  2004).	   In	  addition	  to	  that	  cytoplasmic	  function,	  APC	  has	  recently	  been	  
shown	   to	   perform	   nuclear	   functions	   that	   include	   interaction	   with	   chromatin	   to	   control	  transcription	  directly	   (Sierra	  et	   al,	  2006).	  To	  better	  understand	   the	  consequences	  of	  APC	  mutations	   in	   colorectal	   cancer,	   it	   is	   vital	   to	   identify	   its	   transcriptional	   target	   genes,	  especially	  the	  poorly	  characterized	  direct	  targets.	  An	  in	  vitro	  system	  was	  devised	  to	  test	  the	  direct	  targets	  of	  APC	  exclusively.	  Whole	  Transcriptome	  Shotgun	  Sequencing	  was	  performed	  on	   a	   colorectal	   cancer	   cell	   line	   with	   activated	   Wnt-­‐signaling,	   either	   in	   the	   presence	   or	  absence	   of	   APC.	  Our	   preliminary	   findings	   showed	   that	  within	   our	  model,	   APC	   deficiency	  results	  in	  abnormal	  activation	  or	  suppression	  of	  nearly	  200	  genes.	  The	  studies	  described	  in	  this	   thesis	   were	   then	   focused	   on	   validating	   these	   findings	   as	   well	   as	   identifying	   which	  individual	   target	   genes	   contribute	   to	   cancerous	   phenotypes.	   Several	   targets	   have	   been	  validated	  and	  await	  further	  functional	  testing.	  The	  goals	  of	  these	  future	  experiments	  are	  to	  better	   categorize	   and	   develop	   new	   therapeutic	   targets	   for	   patients	   afflicted	   with	   APC-­‐deficient	  colorectal	  cancer.	  	  	  
PRELIMINARY	  DATA	  Whole	   Transcriptome	  Shotgun	   Sequencing	   was	  performed	   on	   HCT-­‐116	   cells	  to	   compare	   the	   mRNA	  profiles	   of	   wildtype	   and	   APC	  knockdown	   cells.	   A	   cocktail	  of	   4	   siRNAs	   was	   used	   to	  knock	   down	  APC	  mRNA.	   The	   Figure	  1	  Whole	  Transcriptome	  Shotgun	  Sequence	  data	  normalized	  to	  
fold	  changes	  in	  wildtype	  APC	  HCT-­‐116	  cells	  (red)	  vs.	  APC	  
deficient	  APC	  cancer	  cells	  (blue)	  
mRNA	  profiles	  of	   the	  cell	   lines	  were	   then	  measured	  after	  48	  hours	  after	   the	  knockdown.	  The	  normalized	   findings	   (Figure	  1)	   showed	  a	  2.88	   fold	  decrease	   in	  APC,	   1.64	   increase	   in	  
CDC25A,	  3.03	  decrease	  in	  ABCC3,	  3.13	  increase	  in	  BAMBI,	  and	  essentially	  no	  change	  in	  MYC	  mRNA	   levels.	   HCT-­‐116	   was	   chosen	   as	   a	   colorectal	   cancer	   model	   based	   on	   the	   cell’s	  continuous	   activation	  of	  Wnt-­‐signaling	  due	   to	   a	  mutant	   β-­‐catenin	  protein	   that	   cannot	   be	  degraded,	  despite	  having	  wild-­‐type	  APC.	   	  This	  allowed	  us	  to	  identify	  direct	  targets	  of	  APC	  specifically	   because	   its	   indirect	   regulation	   of	   gene	   expression	   through	   the	  Wnt	   signaling	  pathway	  was	  expected	  to	  have	  a	  limited	  impact	  in	  a	  cell	  line	  with	  degradation-­‐resistant	  β-­‐catenin.	  	  
RESULTS	  The	  cell	  division	  cycle	  25	  (CDC25)	   family	  of	  phosphatases	  provide	  essential	  regulation	  of	  eukaryotic	   cell	   cycles.	   CDC25A,	   specifically,	   is	   required	   for	   progression	   from	  G1	   to	   the	   S	  phase	   of	   the	   cell	   cycle.	   CDC25A	   is	   targeted	   for	   degradation	   in	   response	   to	  DNA	  damage,	  which	   prevents	   chromosomal	   abnormalities	   from	   being	   replicated	   and	   passed	   on	   to	  daughter	   cells.	   CDC25A	   is	   an	   identified	   oncogene,	   although	   its	   exact	   mechanism	   in	   the	  development	  of	  cancer	  has	  not	  been	  well	  characterized	  (Boutros	  et	  al.,	  2007).	  CDC25A	  was	  chosen	   for	   further	   study	   based	   on	   a	   1.64	   fold	   increase	   upon	   knockdown	   of	   APC	   and	   its	  known	  role	  in	  cancer	  development.	  	  ATP-­‐binding	   cassette	   (ABC)	   proteins	   transport	   a	   variety	   of	   molecules	   across	   intra-­‐	   and	  extra-­‐cellular	  membranes.	  ABC	  subfamily	  C	  (ABCC)	   is	  specifically	   involved	  in	  excretion	  of	  toxins	   and	   harmful	   molecules.	   ABCC3	   is	   involved	   in	   multi-­‐drug	   resistance	   but	   its	   exact	  
function	  and	  protein	   interactions	  have	  not	  been	  determined.	  ABCC3	  could	  be	   involved	   in	  expulsion	  of	  specific	  chemotherapeutics,	  leading	  to	  further	  development	  of	  tumors.	  ABCC3	  was	  chosen	  for	  further	  study	  based	  on	  a	  3.03	  fold	  decrease	  upon	  knockdown	  of	  APC	  and	  its	  potential	  role	  in	  cancer	  therapeutics.	  	  	  BMP	   and	   activin	   membrane-­‐bound	   inhibitor	   (BAMBI)	   is	   a	   transmembrane	   glycoprotein	  similar	   to	   the	   type	   I	   receptors	   found	   in	   the	   transforming	   growth	   factor-­‐beta	   (TGF-­‐beta)	  family.	   TGF-­‐beta	   signal	   transduction	   is	   inhibitory	   of	   growth	   and	   stimulating	   of	  differentiation	   in	   colorectal	   epithelium	   (Massague	   et	   al.,	   2000).	   BAMBI,	   however,	   is	   a	  pseudoreceptor	  for	  this	  signaling	  (Sekiya	  et	  al.,	  2004).	  BAMBI	  is	  thought	  to	  limit	  the	  ability	  of	  TGF-­‐beta	  to	  efficiently	  signal,	  which	  limits	  a	  cell	  proliferation	  and	  differentiation.	  BAMBI	  was	  chosen	  for	  further	  study	  based	  on	  a	  3.13	  fold	  increase	  upon	  knockdown	  of	  APC	  and	  its	  known	  interactions	  in	  colorectal	  cancers.	  	  Myelocytomatosis	   oncogene	   (MYC)	   is	   a	   nuclear	   phosphoprotein	   that	   is	   vital	   to	   cell	   cycle	  progression,	   cellular	   transformation,	   and	   apoptosis.	   MYC	   specifically	   functions	   as	   a	  transcription	  factor	  for	  many	  genes	  involved	  in	  the	  described	  functions.	  Overexpression	  or	  amplification	   of	   MYC	   has	   been	   well	   characterized	   and	   leads	   to	   a	   variety	   of	   cancers,	  including	   lymphomas	   in	  humans	   (Murry	  et	   al.,	  1983).	  Of	  particular	   interest	   to	   this	   study,	  MYC	  is	  a	  known	  target	  of	  APC	  (He	  et	  al,	  1998).	  MYC	  was	  chosen	  as	  a	  negative	  control	  based	  on	  a	  lack	  of	  fold	  change	  upon	  loss	  of	  APC	  in	  our	  cell	  models.	  	  	  	  Preliminary	   data	   from	   RNA-­‐seq	   indicate	   that	   in	   APC	   deficient	   cell	   lines,	   the	   important	  tumor	  transcripts	  CDC25A,	  ABCC3,	  and	  BAMBI	  fluctuate	  to	  a	  significant	  degree.	  In	  order	  to	  
verify	  these	  results,	  RT-­‐PCR	  was	  performed	  in	  three	  technical	  replicates	  on	  the	  same	  cDNA	  that	  was	  used	  for	  RNA-­‐seq	  (SYBR	  Green,	  Applied	  Biosystems).	   	  Results	  of	  this	  experiment	  are	  shown	  in	  Figure	  2.	  The	  RT-­‐PCR	  results	  mimic	  the	  RNA-­‐seq	  data	  very	  closely.	  The	  fold	  changes	  for	  CDC25A,	  BAMBI,	  MYC	  and	  ABCC3	  were	  1.73,	  2.83,	  1.18,	  and	  -­‐2.87	  respectively.	  
This	  represented	  almost	  identical	  fold	  changes,	  thus	  confirming	  our	  preliminary	  data	  from	  RNA-­‐seq.	  	  	  After	  confirmation	  of	  results	  at	  the	  RNA	  level,	  Western	  Blotting	  was	  performed	  in	  order	  to	  confirm	  results	  at	  the	  protein	  level.	  Specific	  antibodies	  to	  APC,	  CDC25A,	  ABCC3,	  BAMBI,	  and	  β-­‐actin	  were	  obtained	  from	  Santa	  Cruz	  Biotechnology	  and	  were	  optimized	  for	  ideal	  signal	  to	   background	   ratio.	   HCT-­‐116	   cells	   were	   double-­‐transfected	   on	   consecutive	   days	   with	  scrambled	  siRNA	  and	  α-­‐APC	  siRNA.	  HCT-­‐116	  cells	  were	  chosen	  based	  on	  the	  genotype	  of	  wildtype	  APC	  with	   constitutively	   activated	  β-­‐catenin.	   Additionally,	  HT-­‐29-­‐APC	   cells	  were	  
Figure	  2	  
RNA	  sequencing	  (blue,	  red,	  and	  green)	  and	  real-­‐time	  Polymerase	  Chain	  Reaction	  (purple,	  teal,	  and	  
orange)	  data	  shown	  side	  by	  side.	  Fold	  changes	  shown	  in	  wildtype	  APC	  HCT-­‐116	  mock	  transfection	  
cells	  were	  normalized.	  Scrambled	  and	  anti-­‐APC	  siRNA	  transfection	  cell	  fold	  changes	  were	  then	  
measured	  against	  the	  normalized	  data.	  
	  
induced	   for	   APC	   expression	   by	   addition	   of	   Zn2+.	   HT-­‐29-­‐APC	   cells	   were	   chosen	   based	   on	  their	   ability	   to	   reverse	   the	   loss	   of	   both	   endogenous	   APC	   alleles	   using	   a	   transgenic	   APC	  under	   the	   control	   of	   a	   metallothionein	   promoter.	   HT-­‐29-­‐APC	   provides	   a	   reliable	  complement	   to	   hct-­‐116	   base	   on	   the	  ability	   to	   control	  APC	   expression.	  Utilizing	   both	   cell	  lines	   for	   analysis	  when	  APC	  is	  present	  and	   absent.	  Therefore	   when	   the	  APC	   regulated	   genes	  are	   up-­‐regulated	   in	  one	   cell	   line,	   they	  should	   theoretically	  be	   suppressed	   in	   the	  other.	  	  Both	  cell	  lines	  were	   then	   harvested	   and	   whole-­‐cell	   lysates	   were	   obtained.	   Bradford	   Assay	   was	   then	  performed	   in	   order	   to	   determine	   protein	   concentration.	   Proteins	  were	   separated	   by	   gel	  electrophoresis	   on	   a	   gradient	   gel.	   Proteins	   were	   transferred	   to	   a	   polyvinyl	   difluoride	  membrane	  and	  western	  blotting	  was	  performed.	  	  
Figure	  3	  
Western	  blot	  of	  APC,	  CDC25A,	  ABCC3,	  and	  β-­‐actin.	  50mg	  of	  protein	  per	  
lane	  and	  run	  on	  a	  4-­‐12%	  gradient	  gel.	  116	  =	  HCT-­‐116	  cell	  line,	  29-­‐A	  =	  HT-­‐
29-­‐APC	  cell	  line,	  α-­‐APC=	  α-­‐APC	  siRNA	  transfection,	  SCR	  =	  srambled	  siRNA	  
transfection,	  Zn2+	  =	  zinc	  induced	  cells,	  and	  No	  Zn2+	  =	  zinc	  free	  cells.	  
Antibodies	  and	  expected	  band	  position	  listed	  on	  right.	  
Upon	  observation	  of	  the	  western	  blot	  for	  APC,	  a	  band	  of	  approximately	  315	  kDa	  was	  seen	  in	  the	  HCT-­‐116	  protein	  lanes,	  with	  the	  band	  being	  much	  darker	  in	  the	  scrambled	  siRNA.	  In	  the	  HT-­‐29-­‐APC	  cellular	  protein	  lanes,	  bands	  of	  approximately	  315,	  200,	  and	  100	  kDa	  were	  observed	   in	   the	  zinc	   induced	   lanes,	  but	  only	  bands	  of	  200	  and	  100	  kDa	  were	  seen	   in	   the	  zinc	   free	   cellular	   protein	   lanes.	   The	  western	   blot	   for	  APC	  demonstrated	   the	   expect	   band	  sizes	   of	   312	   kDa	   for	   full	   length	   APC	   and	   the	   appropriate	   100	   and	   200	   kDa	   lengths	   for	  truncated	   APC.	   This	   demonstrated	   that	   the	   α-­‐APC	   siRNA	   transfection	  was	   successful	   for	  knocking	  down	  APC	  in	  HCT-­‐116	  cells.	  The	  lack	  of	  a	  band	  at	  312	  kDa	  in	  the	  HT-­‐29-­‐APC	  zinc	  free	   lane	   showed	   that	   the	   zinc	   specific	   metallothionein	   promoter	   was	   successfully	  repressed	  when	  zinc	  was	  absent.	  A	  band	  at	  312	  kDa	  in	  the	  zinc-­‐induced	  lane	  demonstrated	  the	  activation	  of	  the	  metallothionein	  promoter	  when	  zinc	  is	  present.	  	  	  The	  CDC25A	  western	  blot	  demonstrated	  bands	  at	  approximately	  60	  kDa	   in	  all	   lanes.	  The	  bands	   looked	   larger	   in	   both	   the	  α-­‐APC	   siRNA	  and	   zinc	   free	   lanes	  when	   compared	   to	   the	  scrambled	   siRNA	   and	   zinc	   induced	   lanes	   respectively.	   Bands	   at	   60	   kDa	   matches	   the	  expected	  CDC25A	  molecular	  weight	  of	  59	  kDa.	  Upon	  further	  observation,	  the	  bands	  in	  the	  scrambled	   siRNA	   qualitatively	   appear	   to	   be	   about	   half	   the	   intensity	   of	   the	   α-­‐APC	   siRNA	  bands.	  Additionally,	  the	  zinc	  free	  HT-­‐29-­‐APC	  band	  also	  appears	  about	  half	  the	  strength	  of	  the	  zinc	  induced.	  This	  confirms	  the	  RNA	  sequencing	  data	  and	  rtPCR	  data,	  that	  when	  APC	  is	  downregulated	  CDC25A	   is	  upregulated.	  This	   confirmation	   lead	   to	   further	   investigation	  of	  APC	  and	  CDC25A	  influence	  on	  cell	  cycle.	  	  The	  ABCC3	  western	  showed	  bands	  of	  approximately	  250,	  140,	  110,	  80,	  65,	  and	  50	  kDa	  in	  the	  HCT-­‐116	  cellular	  protein	   lanes.	  The	  bands	   looked	  qualitatively	  the	  same	  in	  each	   lane.	  
HT-­‐29-­‐APC	  cell	  lines	  showed	  bands	  of	  approximately	  80,	  65,	  and	  50	  kDa.	  Again,	  the	  bands	  look	  approximately	  the	  same	  darkness	   in	  both	   lanes.	  The	  expected	  molecular	  weights	   for	  ABCC3	   isoforms	  recognized	  by	  our	  antibody	  were	  169,	  127,	  65,	  55	  and	  32	  kDa.	  The	  only	  band	   to	   match	   up	   was	   the	   65	   kDa	   band	   and	   it	   was	   fairly	   weak	   in	   all	   four	   lanes.	   The	  strongest	  band	  appeared	  at	  approximately	  80	  kDa,	  which	  leads	  to	  the	  thought	  that	  this	  is	  perhaps	   non-­‐specific	   binding	   of	   other	   proteins.	   The	   lack	   of	   relevant	   bands	   leads	   to	  inconclusive	  results	  for	  ABCC3.	  Further	  investigation	  into	  cellular	  concentrations	  of	  ABCC3	  in	   our	   cell	   lines	   need	   to	   be	   performed	   before	   a	   conclusion	   can	   be	   drawn	   about	   the	  antibody’s	  specificity.	  	  	  The	  β-­‐actin	  western	   showed	  bands	  of	   approximately	  45	  kDa	   in	  all	   lanes.	   In	   the	  HCT-­‐116	  lanes,	  the	  band	  is	  much	  darker	  in	  the	  α-­‐APC	  lane	  and	  very	  faint	  in	  the	  scrambled	  lane.	  The	  bands	  look	  approximately	  the	  same	  in	  the	  HT-­‐29-­‐APC	  lanes.	  	  The	  only	  band	  observed	  in	  the	  β-­‐actin	  western	  was	   at	   approximately	   45	   kDa.	   This	   observation	   correlates	  well	  with	   the	  expected	  band	   length	  of	  42	  kDa.	   In	   the	  HT-­‐29-­‐APC	   lanes,	   it	  appears	   that	   the	   loading	  was	  very	  similar.	  However,	  in	  the	  HCT-­‐116	  lanes	  there	  appears	  to	  be	  a	  discrepancy	  in	  that	  the	  α-­‐APC	   lane	   appears	   to	   be	   overloaded.	   This	   is	   not	   a	   large	   concern	   because	   APC	  was	   still	  successfully	  knocked	  down	   in	   the	  overloaded	   lane.	   It	   is	   a	   concern	   regarding	   the	  CDC25A	  interpretation	   because	   the	   underloaded	   lane	   showed	   less	   CDC25A.	   However,	   our	  preliminary	   data	   shows	   that	   β-­‐actin	   shows	   a	   1.26	   fold	  mRNA	   increase	  with	   loss	   of	   APC,	  which	  could	  explain	   some	  of	   the	  discrepancies	   shown	  between	  knockdown	  and	  wildtype	  APC.	   β-­‐actin	   upregulation	   is	   repeatedly	   seen	   in	   APC	   knockdown	   cell	   lines	   at	   the	   protein	  level	  as	  well.	  	  
	  Based	  on	  the	  results	  of	  CDC25A	  RT-­‐PCR	  and	  western	  blotting,	  further	  investigation	  of	  APC-­‐CDC25A	   impact	   on	   cell	   cycle	  was	   performed.	  HCT-­‐116	   cells	  were	   prepared	   again	  with	   a	  mock,	   scrambled	   siRNA,	   and	   α-­‐APC	   siRNA	   transfection.	   HT-­‐29-­‐APC	   cells	   were	   also	  prepared	   in	   an	   APC	   induced	   and	   uninduced	   medium.	   1.37	   x	   105	   cells	   of	   each	   of	   the	   5	  samples	  were	   fixed	   in	   ethanol	   and	   resuspended	   in	   a	   propidium	   iodide	   staining	   solution.	  The	  cells	  were	  then	  taken	  to	  the	  Flow	  Cytometry	  Lab	  at	  The	  Ohio	  State	  University	  and	  cell	  cycle	  analysis	  was	  performed.	  	  Results	  of	  HCT-­‐116	  cell	  cycle	  analysis	  (Figure	  4)	  showed	  that	  in	  the	  mock	  transfection	  cells,	  
37.44%	  were	  in	  G1,	  15.50%	  were	  in	  G2/M,	  and	  47.06%	  were	  in	  S.	  For	  the	  scrambled	  siRNA	  transfected	  cells,	  43.28%	  were	  in	  G1,	  10.60%	  were	  in	  G2/M,	  and	  46.12%	  were	  in	  S.	  Lastly,	  for	  the	  α-­‐APC	  siRNA	  transfected	  cells,	  30.39%	  were	  in	  G1,	  22.94%	  in	  G2,	  and	  46.66%	  in	  S.	  The	  results	  for	  HCT-­‐116	  cells	  indicate	  that	  G1	  to	  S	  phase	  transition	  increases	  by	  7.05%	  and	  12.89%	   when	   an	   α-­‐APC	   siRNA	   transfection	   is	   compared	   to	   mock	   and	   scrambled	   siRNA	  transfections	  respectively.	  This	  is	  an	  expected	  result	  because	  APC	  is	  known	  to	  have	  a	  role	  
Figure	  4	  
Cell	  cycle	  analysis	  using	  propidium	  iodide	  staining	  on	  HCT-­‐116	  cells	  under	  mock,	  scrambled	  siRNA,	  
and	  α-­‐APC	  siRNA	  transfections.	  G1,	  S,	  and	  G2/M	  phase	  percentages	  were	  estimated	  using	  ModFIT	  
software.	  
	  
in	   suppressing	  proliferation	   (Morin	  et	   al.,	   1996).	   In	   addition,	   this	   follows	  our	   hypothesis	  because	  when	  APC	   is	  knocked	  down	  CDC25A	  is	  upregulated	  and	  the	  cell	  should	  progress	  through	  the	  G1/S	  phase	  checkpoint	  more	  efficiently.	  	  	  Results	  of	  HT-­‐29-­‐APC	  cell	  cycle	  analysis	  showed	  that	  in	  zinc	  free	  media	  cells,	  41.92%	  were	  in	  G1,	   16.18%	  were	   in	  G2/M,	   and	   41.90%	  were	   in	   S.	   For	   the	  APC	   induced	   cells,	   53.80%	  were	  in	  G1,	  14.47%	  were	  in	  G2/M,	  and	  31.73%	  were	  in	  S.	  	  
Again,	   these	   results	   are	   expected	   because	   APC	   is	   known	   to	   play	   a	   role	   in	   the	  downregulation	   of	   cell	   proliferation.	  However,	   these	   results	   are	   also	   consistent	  with	   our	  hypothesis	  that	  when	  APC	  is	  present,	  CDC25A	  is	  downregulated	  and	  cells	  should	  stop	  at	  the	  G1	  to	  S	  checkpoint	  more	  frequently.	  Therefore	  when	  APC	  is	  knocked	  down	  or	  absent,	  as	  in	  the	   α-­‐APC	   siRNA	   transfection	   or	   uninduced	   HT-­‐29-­‐APC,	   the	   cells	   should	   progress	   more	  rapidly	   through	   the	  G1	   to	  S	  phase	  checkpoint.	  The	   results	   for	   the	  HT-­‐29-­‐APC	   indicate	  an	  11.88%	   difference	   when	   comparing	   the	   G1	   phase	   percentages	   for	   zinc	   free	   vs	   zinc	  
Figure	  5	  
Cell	  cycle	  analysis	  using	  propidium	  iodide	  staining	  on	  HT-­‐29-­‐APC	  cells	  in	  zinc	  free	  or	  100μM	  zinc	  
media.	  G1,	  S,	  and	  G2/M	  phase	  percentages	  were	  estimated	  using	  ModFIT	  software.	  
	  
induction	  media.	  We	  hypothesize	  that	  when	  APC	  is	  knocked	  down,	  cellular	  concentration	  of	  CDC25A	  are	  elevated	  and	  cells	  spend	  less	  time	  in	  the	  G1	  phase	  when	  compared	  to	  wildtype	  APC.	  These	  experiments	  have	  established	  a	  correlation	  and	  the	  current	  system	  allows	  for	  further	  experiments	  to	  test	  causation	  by	  CDC25A.	  	  	  
DISCUSSION	  There	   are	   only	   two	   well-­‐characterized	   targets	   of	   APC	   that	   are	   individually	   sufficient	   to	  contribute	  to	  tumorigenesis,	  MYC	  and	  cyclin	  D1	  (Shtutman	  et	  al,	  1999;	  He	  et	  al,	  1998).	  The	  purpose	   of	   this	   experiment	   is	   to	   identify	   other	   proteins	   that	   have	   well	   characterized	  functions	  and	  are	  also	  potential	   targets	  of	  APC.	  Once	   these	  proteins	  have	  been	   identified,	  experimental	   procedures	   could	   then	   be	   used	   to	   determine	   the	   significance	   of	   the	   APC-­‐protein	   interaction.	   The	   results	   of	   these	   experiments	   would	   potentially	   identify	   new	  therapeutic	   targets	   and	   contribute	   to	   the	   knowledge	   of	   tumorigenesis	   and	   cancer	  development.	  	  	  Whole	   Transcriptome	   Shotgun	   Sequencing	  was	   performed	   on	  HCT-­‐116	   cells	   to	   compare	  the	  mRNA	  profiles	  of	  wildtype	  and	  APC	  knockdown	  cells.	  The	  results	  of	  the	  RNAseq	  were	  used	  to	  identify	  potential	  targets	  for	  APC.	  Targets	  were	  narrowed	  down	  and	  selected	  based	  on	   fold	   changes	   and	   the	   target’s	   known	   cancerous	   properties.	   In	   order	   to	   confirm	  transcription	   levels	   in	   the	  RNA-­‐seq	  data,	  RT-­‐PCR	  was	  performed	  on	  HCT-­‐116	   cells	   using	  the	  same	  cDNAs	  previously	  used	  in	  the	  RNA	  sequencing.	  4	  targets	  were	  confirmed	  by	  the	  RT-­‐PCR	   experiment.	   Western	   blotting	   was	   then	   performed	   on	   the	   3	   targets	   (CDC25A,	  
ABCC3,	   and	   BAMBI)	   in	   order	   to	   confirm	   protein	   concentration	   levels	   in	   relation	   to	   the	  transcription	  fold	  changes	  shown	  in	  the	  RNA-­‐seq	  and	  RT-­‐PCR	  data.	  	  Western	  blotting	  qualitatively	  confirmed	  CDC25A	  protein	  levels	  but	  provided	  inconclusive	  results	   for	   ABCC3	   (Figure	   3).	   ABCC3	   still	   has	   potential	   to	   advance	   into	   further	  experimentation,	   but	   a	  more	   defined	  western	   blot	   must	   first	   be	   obtained.	   MYC	  was	   not	  chosen	  for	  further	  study	  based	  on	  a	  lack	  of	  fold	  changes	  in	  the	  absence	  of	  APC.	  BAMBI	  had	  no	  acceptable	  antibody,	  so	  experimentation	  was	  placed	  on	  hold	  until	  a	  suitable	  one	  could	  be	  found.	  	  	  CDC25A	  was	  then	  chosen	  for	  further	  analysis	  based	  on	  the	  fact	  that	  the	  western	  blot	  results	  confirmed	  the	  experimental	  hypothesis.	  Cell	  cycle	  analysis	  by	  flow	  cytometry	  was	  chosen	  as	  a	  pilot	   study	   for	   the	  effect	  of	  APC	  changes	  on	   the	  cell	   cycle.	  The	  study	  was	  performed	  using	  propidium	  iodide	  on	  HCT-­‐116	  and	  HT-­‐29-­‐APC	  cells.	  APC	  cellular	  concentrations	  were	  manipulated	   and	   the	   cells	   were	   taken	   to	   the	   Flow	   Cytometry	   Lab	   at	   The	   Ohio	   State	  University.	  	  Cell	  cycle	  analysis	  demonstrated	  that	  APC	  deficient	  cells	  progress	  through	  the	  G1/S	  phase	  checkpoint	  at	  an	  increase	  of	  7.05%	  and	  12.89%	  in	  HCT-­‐116	  cells	  and	  11.88%	  in	  HT-­‐29-­‐APC	  when	  compared	  to	  cells	  with	  wildtype	  APC.	  	  	  CDC25A	   is	   a	  phosphatase	   responsible	   for	   cellular	  progression	   through	   the	  G1	   to	  S	  phase	  checkpoint.	  This	  function	  is	  pivotal	  for	  cellular	  development	  and	  proliferation.	  As	  a	  result	  of	  this	  function,	  CDC25A	  has	  been	  found	  to	  be	  overexpressed	  in	  a	  variety	  of	  cancer,	  which	  include	   breast	   and	   colorectal	   (Sansom	   et	  al.,	  2007;	   Tetso	   et	  al.,	   1999).	   Therefore	   further	  analysis	   of	   APC-­‐CDC25A	   interaction	   could	   provide	   vital	   information	   into	   how	   colorectal	  cancers	  develop	  rapidly	  proliferating	  phenotypes.	  
	  Further	   analysis	   of	   CDC25A	   must	   be	   performed	   in	   order	   to	   better	   characterize	   the	  relationship	   between	   APC	   and	   CDC25A,	   however	   the	   pilot	   study	   provided	   a	   good	  foundation	   for	   further	   investigation	   into	   our	   hypothesis.	   In	   order	   to	   test	   if	   CDC25A	   is	  sufficient	  to	  cause	  progression	  though	  the	  G1/S	  phase	  checkpoint	  when	  APC	  is	  wild	  type,	  an	   overexpression	   experiment	  must	   be	   performed.	   This	  would	   be	   accomplished	   through	  the	  use	  of	  a	  vector	  to	  transfect	  CDC25A	  directly	  into	  HCT-­‐116	  cells.	  HCT-­‐116	  cells	  would	  be	  used	   based	   on	   the	   fact	   that	   it	   has	   wild	   type	   APC	   and	   lower	   cellular	   concentrations	   of	  CDC25A.	  Therefore,	  overexpression	  is	  meaningful.	  CDC25A	  overexpression	  would	  need	  to	  be	  optimized	  in	  order	  to	  determine	  the	  fold	  change	  impact	  of	  CDC25A	  increase.	  	  	  In	  order	  to	  determine	   if	  CDC25A	  is	  necessary	  for	  cell	  cycle	  progression	  through	  the	  G1/S	  phase	   checkpoint	   in	   cells	   with	   loss	   of	   APC,	   a	   knockdown	   of	   CDC25A	   would	   need	   to	   be	  performed.	   This	   could	   be	   accomplished	   with	   a	   α-­‐CDC25A	   and	   α-­‐APC	   siRNA	   double	  transfection	  into	  HCT-­‐116	  cells.	  Knockdown	  of	  both	  APC	  and	  CDC25A	  is	  necessary	  because	  CDC25A	   is	   present	   at	   a	   low	   cellular	   concentration	   in	  HCT-­‐116	   cells.	   This	  would	  model	   a	  cancerous	  human	  cell	  in	  which	  APC	  is	  deficient.	  This	  would	  allow	  for	  the	  characterization	  of	  CDC25A’s	  necessity	  for	  polyp	  formation.	  Again,	  optimization	  of	  the	  knockdown	  would	  be	  ideal	  in	  order	  to	  determine	  the	  effect	  of	  fold	  decrease	  of	  CDC25A.	  Cell	  cycle	  analysis	  would	  be	  performed	  in	  both	  knockdown	  and	  upregulated	  experiments	  and	  the	  results	  would	  be	  compared	  to	  controls.	  	  	  An	  additional	   requirement	   to	   the	  knockdown	  and	  upregulation	  experiments	  would	  be	   to	  perform	  both	  experiments	   in	  a	   cell	   cycle	   synchronization	  environment.	   Serum	  starvation	  
can	  stop	  cell	  cycle	  progression,	  leaving	  cells	  arrested	  in	  the	  G1	  phase.	  Once	  all	  cell	  are	  in	  G1	  phase,	   serum	   could	   be	   added	   back	   and	   growth	   would	   be	   allowed	   to	   progress.	   Periodic	  measurements	  could	  then	  be	  taken	  in	  order	  to	  determine	  if	  knockdown	  APC	  and	  wildtype	  CDC25A	   progress	   through	   the	   G1/S	   phase	   checkpoint	   faster	   than	   APC/	   CDC25A	  knockdown	  cells.	  	  	  In	   addition	   to	   the	   short-­‐term	   future	   of	   this	   experiment,	   larger	   goals	   would	   to	   be	   to	  determine	   CDC25A’s	   role	   in	   cancer	   in	   vivo,	   with	   a	   focus	   on	   determining	   if	   CDC25A	   is	  necessary	   for	   clinical	   phenotypes	   observed	   in	   colorectal	   cancers.	   This	   could	   be	  accomplished	  through	  the	  use	  of	  mouse	  models.	  A	  CDC25A	  deficient	  transgenic	  mouse	  line	  could	  be	  crossed	  to	  APC	  deficient	  mouse	  lines,	  compared	  to	  APC	  deficient	  mouse	  lines	  with	  wildtype	   CDC25A.	   Polyp	   formation	   would	   be	   allowed	   to	   progress	   and	   tumor	   numbers	  would	  then	  be	  counted.	  According	  to	  the	  data	  of	  this	  experiment,	  it	  would	  be	  expected	  that	  that	   the	   CDC25A	   deficient	   mouse	   lines	   would	   develop	   fewer	   polyps	   when	   compared	   to	  wildtype	  CDC25A.	  	  	  This	   experiment	   has	   provided	   a	   hypothesis	   that	   in	   APC	   deficient	   cells,	   CDC25A	   is	  overexpressed	   and	   cells	   progress	   through	   the	  G1/S	  phase	   checkpoint	  more	   rapidly.	   This	  provides	   a	   foundation	   for	   further	   investigation	   into	   APC-­‐CDC25A	   interaction,	   with	   the	  hopes	   of	   characterizing	   another	   target	   gene	   for	   APC.	   If	   characterized,	   it	   could	   provide	  another	   method	   to	   target	   APC	   deficient	   cancers.	   CDC25A	   is	   already	   the	   target	   for	  therapeutics	  such	  as	  quinones	  (Garuti	  et	  al,	  2008),	  which	  reflects	  its	  importance	  in	  cancer	  cells	   is	   already	  well	   known.	   CDC25A	   could	  become	   a	  more	   important	   therapeutic	   target,	  while	  also	  allowing	  for	  better	  diagnosis	  and	  prognosis	  for	  APC	  deficient	  cancer	  patients.	  
	  
MATERIAL	  AND	  METHODS	  
APC	  knockdown	  in	  HCT-­‐116	  Cells	  [The	   following	   protocol	   was	   generated	   from	   the	   Thermo	   Scientific	   DharmaFECT	  Transfection	   Reagent	   Protocol	   for	   siRNAs]	   Scrambled	   siRNA	   (not	   actually	   a	   scrambled	  version	   of	   any	   of	   the	   α-­‐APC	   sequences)	   and	   α-­‐APC	   siRNA	   pools	   from	   Dharmacon	   were	  resuspended	  to	  a	   final	  concentration	  of	  10μM	  in	  Thermo’s	  1X	  siRNA	  buffer	  (6mM	  HEPES	  pH	  7.3-­‐7.6,	  60mM	  KCL,	  0.02mM	  MgCl2).	  In	  6-­‐well	  plates,	  1x105	  HCT-­‐116	  cells	  were	  plated	  per	   well	   20	   hours	   before	   transfection.	   The	   HCT-­‐116	   cells	   were	   cultured	   in	   McCoy’s	   5A	  media	  +	  10%	  FBS.	  	  	  On	  the	  day	  of	  the	  transfection	  5μL	  of	  10μM	  siRNA	  (scrambled	  control	  or	  α-­‐APC	  pool)	  was	  combined	  with	   195μL	   serum-­‐free	  McCoy’s	   5A	  media	   and	  mixed.	   In	   a	   separate	   tube,	   4μL	  DharmaFECT2	   transfection	   reagent	   was	   combined	   with	   196μL	   serum-­‐free	   media	   and	  mixed.	  The	  tubes	  were	  incubated	  separately	  at	  room	  temperature	  for	  5	  minutes,	  and	  then	  combined	  into	  a	  single	  tube.	  The	  combination	  was	  incubated	  for	  exactly	  20	  minutes.	  Along	  with	   the	  scrambled	  control	  and	  α-­‐APC,	  a	  mock	   transfection	  was	  set	  up	   that	  contained	  no	  siRNA.	  The	  transfection	  mixture	  was	  added	  to	  1.6	  mL	  of	  10%	  FBS	  in	  McCoy’s	  5A	  media.	  	  	  The	   media	   from	   the	   HCT-­‐116	   well	   plates	   was	   aspirated	   and	   replaced	   with	   2mL	   of	   the	  transfection	   media	   mixture.	   The	   cells	   were	   incubated	   in	   the	   transfection	   mixture	   for	   6	  hours.	  The	  media	  was	   then	  aspirated	  and	  replaced	  with	  2mL	  of	  pre-­‐warmed	  McCoy’s	  5A	  media	  +	  10%	  FBS.	  The	  cells	  were	   incubated	  for	  another	  8	  hours	  and	  an	  additional	  media	  change	   was	   performed.	   After	   24	   hours,	   the	   transfection	   was	   repeated	   exactly	   as	   the	  
previous	   steps	   described.	   The	   transfection	   media	   was	   again	   changed	   6	   hours	   after	   the	  transfection	  with	   2mL	   of	   pre-­‐warmed	  McCoy’s	   5A	  media	   +	   10%	   FBS	   and	   again	   8	   hours	  later.	  	  	  In	  addition	  to	  these	  two	  media	  changes,	  additional	  media	  changes	  were	  performed	  24	  and	  32	   hours	   after	   the	   second	   transfection,	   for	   a	   total	   of	   4	   media	   changes	   after	   the	   second	  transfection.	   The	   purpose	   of	   these	   changes	   is	   to	   remove	   residual	   inactive	   transfection	  complexes	  and	   transfection	   reagents,	   as	   these	  will	   cause	   cell	  harm	  and	  death.	  Cells	  were	  harvested	  48	  hours	   after	   the	   second	   transfection	  using	  RIPA	  buffer	   (50	  mM	  Tris-­‐HCl	   pH	  8.0,	   150	   mM	   NaCl,	   0.1%	   SDS,	   0.5%	   sodium	   deoxycholate,	   1%	   NP-­‐40	   alternative,	   1	   mM	  EDTA,	  1	  mM	  PMSF,	  1%	  Roche	  Mammalian	  protease	  inhibitor	  cocktail)	  in	  order	  to	  recover	  whole	  cell	  lysates.	  	  	  
APC	  induction	  in	  HT-­‐29-­‐APC	  cells	  	  HT-­‐29-­‐APC	  cells	  were	  maintained	   in	  McCoy’s	  5A	  media	  supplemented	  with	  10%	  FBS	  and	  0.6	  μg/mL	  Hygromycin	  B.	  The	  HT-­‐29-­‐APC	  cells	  were	  plated	  in	  a	  6-­‐well	  plate	  at	  a	  density	  of	  2	   x	   105	   cells/well.	   24	   hours	   later,	   zinc-­‐containing	   media	   was	   prepared	   to	   a	   final	  concentration	  of	  100	  mM.	  The	  media	  was	  aspirated	  off	  of	  the	  cells	  in	  the	  6-­‐well	  plate	  and	  3	  mL	   of	   the	   zinc-­‐chloride	   media	   was	   added	   to	   3	   of	   the	   wells	   (the	   other	   3	   were	   left	   for	  controls).	  	  The	  cells	  were	  incubated	  48	  hours	  before	  harvesting.	  APC	  expression	  will	  be	  higher	  at	  24	  hours	  after	  zinc-­‐induction	   than	  at	  48	  hours,	  but	   the	  extra	  day	  allows	  more	   time	   for	  APC-­‐driven	  transcription	  changes	  to	  translate	  to	  the	  protein	  level	  of	  expression.	  The	  cells	  were	  
harvested	   in	  RIPA	  buffer	  (50	  mM	  Tris-­‐HCl	  pH	  8.0,	  150	  mM	  NaCl,	  0.1%	  SDS,	  0.5%	  sodium	  deoxycholate,	   1%	   NP-­‐40	   alternative,	   1	   mM	   EDTA,	   1	   mM	   PMSF,	   1%	   Roche	   Mammalian	  protease	  inhibitor	  cocktail)	  in	  order	  to	  recover	  whole	  cell	  lysates.	  	  	  
Real	  Time-­‐PCR	  HCT-­‐116	   cells	  were	  plated	   and	   treated	  with	   a	  mock,	   scrambled	   siRNA,	   and	  α-­‐APC	   siRNA	  transfections	   according	   to	   the	   protocol	   described	   above.	   Total	   RNA	  was	   harvested	   from	  each	   cell	   condition	   and	   a	   TRUseq	   RNA-­‐seq	   sample	   preparation	   kit	   was	   used	   to	   isolate	  mRNA	  and	  prepare	  cDNA	  libraries.	  These	  samples	  had	  previously	  been	  analyzed	  by	  RNA-­‐seq	  and	  the	  same	  cDNA	  was	  used	  as	  a	  template	  for	  this	  RT-­‐PCR.	  To	  set	  up	  the	  RT-­‐PCR,	  three	  reactions	   for	   each	   transfection	   condition	   was	   used	   in	   a	   combination	   of	   cDNA	   +	   protein	  specific	  primer.	  Primers	  were	  designed	  to	  the	  coding	  sequence	  of	  BAMBI,	  ABCC3,	  CDC25A,	  and	  MYC,	  and	  were	  previously	  optimized	  for	  final	  concentration.	  Three	  reactions	  were	  set	  up	  for	  each	  transfection	  condition	  in	  relation	  to	  BAMBI	  according	  to	  the	  follow	  formula:	  1	  ng	  of	  cDNA	  and	  300	  nM	  of	  BAMBI	  primer	  set.	  Similarly,	  for	  ABCC3:	  1	  ng	  of	  cDNA	  and	  300	  nM	  of	  ABCC3	  primer	  set	  were	  used.	  A	  similar	  formula	  was	  used	  for	  CDC25A:	  1	  ng	  of	  cDNA	  and	  900	  nM	  of	  CDC25A	  primer	  set.	  Lastly,	  for	  MYC:	  1	  ng	  of	  cDNA	  and	  50	  nM	  of	  MYC	  primer	  set	   were	   used.	   The	   reactions	  were	   brought	   up	   to	   a	   volume	   of	   10	   μL	  with	   nuclease	   free	  water	  and	  2X	  SYBR	  Green	  PCR	  master	  mix	  was	  added	  in	  equal	  volumes.	  The	  reactions	  were	  then	  taken	  to	  the	  Shared	  Resources	  at	  The	  Ohio	  State	  University	  for	  RT-­‐PCR	  analysis.	  	  	  
Western	  Blotting:	  Preparing	  Whole	  Cell	  Lysates	  HT-­‐29-­‐APC	   and	   HCT-­‐116	   cells	   were	   transfected	   according	   to	   the	   procedure	   described	  above.	  Adherent	  cells	  were	  harvested	  from	  10-­‐cm2	  plates	  by	  washing	  once	  with	  Dulbecco’s	  
PBS	  and	  then	  scraped	  for	  removal.	  The	  cells	  were	  placed	  in	  a	  15mL	  Falcon	  tube	  and	  spun	  for	  5	  minutes	  at	  1000	  rpm	  (170g).	  The	  supernatant	  was	  aspirated	  and	  the	  cells	  were	  placed	  on	  ice.	  The	  solid	  cell	  volume	  was	  estimated	  to	  be	  30μL	  and	  4	  volumes	  (120μL)	  of	  cold	  NP-­‐40	   lysis	   buffer	   (50mM	  Tris-­‐HCl	  pH	  8.0,	   150mM	  NaCl,	   1%	  NP-­‐40	   alternative,	   5mM	  EDTA,	  1mM	  PMSF,	  1%	  Roche	  mammalian	  protease	   inhibitor	  cocktail)	  was	  used	   for	  APC	  protein	  recovery	  and	  RIPA	  buffer	  (50	  mM	  Tris-­‐HCl	  pH	  8.0,	  150	  mM	  NaCl,	  0.1%	  SDS,	  0.5%	  sodium	  deoxycholate,	   1%	   NP-­‐40	   alternative,	   1	   mM	   EDTA,	   1	   mM	   PMSF,	   1%	   Roche	   Mammalian	  protease	  inhibitor	  cocktail)	  for	  recovery	  of	  whole	  cell	  lysates.	  	  	  The	   cell	   pellet	   was	   resuspended	   and	   transferred	   to	   a	   pre-­‐chilled	   Eppendorf	   tube.	   The	  mixture	  was	   incubated	  on	   ice	   for	  15	  minutes	   and	   then	   centrifuged	  at	  13,000	   rpm	   for	  15	  minutes.	  The	   supernatant	  was	  divided	   into	  30	  uL	  aliquots	  and	  snap-­‐froze	  by	  dry	   ice	  and	  ethanol.	  The	  samples	  not	  in	  use	  were	  stored	  at	  -­‐80°C.	  	  	  
Bradford	  Assay	  A	  series	  of	  dilutions	  of	  0μg/mL,	  5μg/mL,	  10μg/mL,	  15μg/mL,	  and	  20μg/mL	  was	  prepared	  of	   Bovine	   Serum	   Albumin	   (BSA),	   and	   the	   total	   volume	   was	   brought	   up	   to	   798μL	   with	  double-­‐distilled	  water.	   2μL	   of	   lysis	   buffer	  was	   then	   added	   to	   each	  BSA	   control.	   For	   each	  experimental	  cell	  sample,	  798μL	  of	  double-­‐distilled	  water	  was	  placed	  into	  cuvettes,	  along	  with	  2μL	  of	  cellular	  sample.	  Into	  both	  the	  control	  and	  the	  experimental	  samples,	  200μL	  of	  BioRad	  Protein	  Assay	  Dye	  Reagent	   (Coomassie	  Brilliant	  Blue	  G-­‐250	   Solution)	  was	   added	  into	  each	  cuvette.	  The	  mixtures	  were	  incubated	  for	  10	  minutes	  at	  room	  temperature.	  The	  measurements	  for	  each	  of	  the	  BSA	  solutions	  were	  measured	  against	  a	  the	  0μg/mL	  control	  in	  order	   to	   create	  a	  known	  protein	   concentration	   curve.	  The	  experimental	   samples	  were	  
then	  measured	  against	   the	  0μg/mL	  control.	  The	  protein	   readings	  were	  obtained	   through	  the	  use	  of	  a	   spectrophotometer.	  The	  samples	  were	   then	  compared	   to	   the	  standard	  curve	  established	  protein	  control	  of	  BSA	  in	  order	  to	  determine	  sample	  protein	  concentration.	  	  	  
Western	  Blotting:	  Gel	  Electrophoresis	  A	  precast	  4-­‐12%	  gradient	  gel	  (Novex)	  was	  loaded	  with	  50μg	  of	  protein	  sample	  according	  to	  the	  Chart	  1	  and	  run	  for	  approximately	  2	  hours	  at	  100	  V.	  	  	   Lane	  1	   Lane	  2	   Lane	  3	   Lane	  4	   Lane	  5	  Sample	   Protein	  Ladder	   α-­‐APC	  siRNA	  HCT-­‐116	   Scrambed	  siRNA	  HCT-­‐116	   Zinc	  Induced	  HT-­‐29-­‐APC	  	   Zinc	  Free	  HT-­‐29-­‐APC	  	   	  	  5X	  transfer	  buffer	  (387	  mM	  glycine,	  50	  mM	  Tris	  Base,	  5%	  methanol)	  was	  made	  and	  the	  gel	  was	  equilibrated	  with	  the	  buffer	  for	  1	  minute.	  The	  gel	  was	  then	  set	  up	  for	  electrophoresis	  to	  a	  polyvinyl	  difluoride	  membrane	  (PVDF).	  Electrophoresis	  was	  performed	  for	  16	  hours	  at	  200	  mA	  at	  a	  temperature	  of	  4°C.	  The	  PVDF	  membrane	  was	  blocked	  for	  2	  hours	  in	  TBST	  that	  contains	  both	  10%	  milk.	  	  The	   primary	   antibodies	   for	   APC,	   CDC25A,	   ABCC3,	   and	   β-­‐actin	  were	   obtained	   from	   Santa	  Cruz	   Biotechnology.	   The	   primary	   antibodies	   were	   placed	   in	   10%	  milk	   according	   to	   the	  following	   concentrations:	   1:500	   for	   CDC25A,	   1:500	   for	   ABCC3,	   1.5	   μg/mL	   for	   APC,	   and	  1:2500	  for	  β-­‐actin.	  The	  membranes	  were	  incubated	  for	  18	  hours	   in	  the	  primary	  antibody	  solution	  on	  a	  shaker	  at	  4°C.	  After	  incubation,	  the	  membranes	  were	  washed	  with	  25	  mL	  of	  TBST	  8	  times	  with	  solution	  changes	  occurring	  every	  5	  minutes.	  The	  membranes	  were	  then	  incubated	   in	   the	   secondary	   antibody	   of	   corresponding	   species-­‐specific	   horseradish	  
Chart	  1	  
Lane	  loading	  sequence	  for	  APC,	  CDC25A,	  ABCC3,	  and	  β-­‐actin	  western	  blots	  
peroxidase	  (HRP)	  at	  a	  concentration	  of	  1:5000.	  Β-­‐actin	  antibody	  has	  HRP	  already	  bound,	  so	  the	  secondary	  step	  was	  not	  performed.	  The	  membranes	  were	  incubated	  in	  the	  secondary	  antibodies	   for	   90	  minutes	   at	   room	   temperature.	   The	   blots	   were	   washed	   with	   25	  mL	   of	  TBST	  14	  times	  with	  solution	  changes	  occurring	  every	  10	  minutes.	  	  	  After	   washing	   the	   membrane,	   1	   ml	   each	   of	   Western	   Lightning	   Enhanced	   ECL	   Luminal	  Reagent	  and	  Western	  Lightning	  Enhanced	  ECL	  Oxidizing	  Reagent	  were	  mixed	  together.	  The	  2	   mL	   solution	   was	   prepared	   and	   added	   to	   each	   membrane	   separately.	   The	   membranes	  were	   incubated	   in	   the	   solution	   for	   1	  minute,	   placed	   in	  plastic	  wrap,	   and	   taken	   to	   a	   dark	  room	  for	  film	  exposure.	  The	  blots	  were	  exposed	  for	  30	  seconds,	  2	  minutes,	  and	  30	  minutes	  and	  the	  film	  was	  developed.	  	  
Cell	  Cycle	  Analysis	  by	  DNA	  Content	  HCT-­‐116	  were	   transfected	   and	  HT-­‐29-­‐APC	  were	   induced	   to	  APC	  expression	  according	   to	  the	   protocols	   described	   above.	   The	   rest	   of	   the	   protocol	  was	   performed	   on	   ice.	   The	   cells	  were	   trypsinized	   and	  washed	   in	   Dulbecco’s	   phosphate	   buffered	   saline	   (PBS).	   They	  were	  then	  centrifuges	  for	  5	  minutes	  at	  200	  g	  at	  4°C.	  They	  were	  resuspended	  again	  and	  2	  x	  106	  cells/mL	  were	  placed	  in	  new	  tubes.	  The	  cells	  were	  centrifuged	  for	  5	  minutes	  at	  	  200	  g	  and	  4°C.	  The	  PBS	  wash	  was	   removed	  and	   the	   cells	  were	   resuspended	   in	  1	  mL	  PBS.	  The	   cells	  were	  vortexed	  gently	   for	  30	  seconds	   to	  break	  up	  any	  cellular	   clumps.	  The	  vortexing	  was	  continued	   on	   the	   cell	   suspension	   and	  7	  mL	  of	   80%	  ethanol	   (previously	   chilled	   to	   -­‐20°C)	  was	  added	  dropwise.	  The	  cells	  were	  then	  incubated	  at	  -­‐20°C	  for	  12	  hours.	  	  	  
The	  cells	  were	  washed	  by	  centrifuging	  for	  10	  minutes	  at	  200g	  and	  4°C,	  removing	  the	  PBS	  and	   suspending	   the	   cells	   in	   1	  mL	   of	   PBS.	   The	   cells	   were	   then	   normalized	   to	   the	   lowest	  concentration	  of	  cells	  present	  in	  the	  5	  samples	  (1.37	  x	  105	  cell/mL)	  and	  brought	  up	  to	  1	  mL	  with	  PBS.	  The	  normalization	  of	  the	  concentration	  allows	  for	  consistent	  staining	  and	  sample	  sizes	   for	   the	   rest	  of	   the	  experiment.	  Once	  all	   samples	  were	  equalized,	   the	  solutions	  were	  transferred	  to	  previously	  chilled	  Falcon	  tubes.	  	  	  Propidium	  Iodide/Triton	  X-­‐100	  staining	  solution	  (2	  mg	  DNAse-­‐free	  RNAse	  A	  and	  400	  μL	  of	  500	   μg/mL	   propidium	   iodide	   brought	   up	   to	   10	  mL	   with	   0.1%	   Triton	   X-­‐100	   solution	   in	  Dulbecco’s	  PBS)	  was	  made.	  Cells	  were	  spun	  down	  for	  15	  minutes	  at	  200	  g	  and	  4°C	  and	  the	  supernatant	   was	   removed.	   The	   cells	   were	   resuspended	   in	   400	   μL	   of	   Propidium	  Iodide/Triton	  X-­‐100	  staining	  solution	  and	  transferred	  to	  Falcon	  flow	  cytometry	  tubes.	  The	  tubes	  were	  wrapped	  in	  aluminum	  foil	  and	  incubated	  at	  room	  temperature	  for	  30	  minutes.	  The	  tubes	  were	  placed	  back	  on	  ice	  and	  filtered	  into	  new	  Falcon	  flow	  cytometry	  tubes	  using	  nylon	  mesh.	  The	  nylon	  mesh	  removes	  any	  cellular	  clumps	  present.	  The	  filtered	  cells	  were	  then	  taken	  to	  the	  Flow	  Cytometry	  Lab	  at	  The	  Ohio	  State	  University	  for	  flow	  cytometry.	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